



The Enhancement of Toxin-Induced Liver Fibrosis in Fatty Liver Disease



Ekihiro Seki, M.D.,Ph.D.
University of California San Diego






Carbon tetrachloride (CCl₄)

- A manufactured chemical.
- Does not exist naturally.
- Clear liquid with a sweet odor that smells like chloroform.
- Easily vaporizes.
- High levels or continuous low dose exposure influence to liver, and cause hepatocyte injury, liver fibrosis and hepatocarcinogenesis.




Trichloromethyl radical
(Free radical)

Lipid peroxidation
Hepatotoxicity



Carbon tetrachloride (CCl_4)

- Has been used for dry-cleaning, solvent, reagent in chemical synthesis, fire extinguisher fluid, and refrigerants.
- The use and production of CCl_4 was declined in the mid 1970s, but it has been diffusing into air, water and soil. It takes for several years to break down
- In air of 0.1 ppb are common around the world.
- In water or soil, ranging from 50 to over 1,000 ppb at 22% of the Superfund sites.
- 47 th and 50 th RANK (2007 CERCLA and 2011 ATSDR priority lists)



NAFLD

- Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of liver disease in the United States
- The prevalence of obesity and diabetes increases
 - 60-70% of obese adults have NAFLD
- 30-40% of adults in the western world have NAFLD
- 15-20% of NAFLD patients progress to NASH
- According to a 2008 estimation, NAFLD will be the leading cause for liver transplantation by 2020.

Question: Does Fatty liver disease affects the sensitivity to toxin exposure?




High fat diet



Chronic Industrial Toxin Exposure



Healthy Liver




Fatty Liver




Activation of Stellate cells in Liver Fibrosis


Carbon tetrachloride, HBV, HCV, NASH, Alcohol



The Effect of Fatty Liver in Toxin-induced Liver Fibrosis




HFD feeding enhances Toxin-induced Liver Injury




8 x CCl₄ (0.25 ul/g BW)


LFD + Oil




HFD + Oil




LFD + CCl₄



HFD + CCl₄






HFD feeding enhances Toxin-induced Liver Inflammation




8 x CCl₄ (0.25 ul/g BW)

HFD feeding enhances Toxin-induced Liver Fibrosis





HFD feeding enhances Toxin-induced Liver Fibrosis





What is the Underlying Mechanism of Increased Sensitivity to CCl_4 ?

High fat diet

Chronic CCl_4 Exposure






Healthy Liver



Fatty Liver

1. Increased sensitivity to hepatocyte death.
2. Increased capacity to produce cytokines.
3. Increased production of extracellular matrix.
4. Increased production of toxic metabolite from CCl_4 .





TGF- β activated kinase 1 (TAK1)

TAK1 is a 78-80 kDa protein, which is encoded by the *MAP3K7* gene.


TAK1 is a serine/ threonine kinase, and belong to MAP3K family.

Phosphorylation and ubiquitination of TAK1 are important for activation of TAK1 and its downstream molecules.



TAK1 interacts with TAB1, TAB2 and TAB3 that regulate TAK1 full activation.

TAK1 is activated in the signaling of TNF, IL-1 β , TLRs and TGF- β .


TAK1 regulates activation of NF- κ B, JNK, p38, AMPK and NLK.




TAK1 Regulates NF- κ B and JNK Pathways, and also Regulates AMPK-Autophagy Pathway



Hepatic TAK1 expression is decreased in advanced fatty liver disease



Hepatic TAK1 expression is decreased in fatty liver with toxin exposure





Does Decreased TAK1 Expression Increase Sensitivity to CCl_4 ?

High fat diet

Chronic CCl_4 Exposure



Healthy Liver




Fatty Liver





Does Decreased TAK1 Play a Role?

Generation of hepatocyte-specific TAK1-deleted mice

Alb-Cre-Tg mice




Tak1 flox/flox mice




CCl₄ exposure augments liver fibrosis in *Tak1*^{ΔHEP} mice

WT-oil





WT-CCl₄



***Tak1*^{ΔHEP}-oil**





***Tak1*^{ΔHEP}-CCl₄**



12 injections
(5-6 month old)

TAK1 deficiency enhanced liver injury and fibrogenic response after chronic exposure to CCl₄









Why Does Decreased TAK1 Expression Increase Sensitivity to CCl₄ Exposure?

- 1. Sensitivity to TNF α -induced hepatocyte death**
- 2. Sensitivity to TGF β -induced hepatocyte death**
- 3. Autophagy in hepatocytes.**

TAK1^{-/-} hepatocytes lack TNF α -induced NF- κ B activation and are susceptible to cell death




TAK1^{-/-} hepatocytes lack TNF α -induced NF- κ B activation and are susceptible to cell death





(Inokuchi et al 2010, PNAS)

TAK1^{-/-} hepatocytes augment TGF β -mediated Smad2/3 activation and are susceptible to cell death




TAK1^{-/-} hepatocytes augment TGFβ-mediated Smad2/3 activation and are susceptible to cell death



(Yang et al 2013, Gastroenterology)





Autophagy

Autophagy is a process to degrade intracellular components (long-lived or aggregated proteins, lipids, and damaged organelles, such as mitochondria) in lysosomes to supply for energy generation for maintaining cellular homeostasis.




—————→ Cell death, Cancer, Fatty Liver, Type II Diabetes, Innate Immune Systems, Aging, Infectious Disease, Toxin exposure, Fibrosis.

Autophagy is suppressed in $TAK1^{\Delta HEP}$ mice





(Inokuchi-Shimizu et al 2014, J Clin Invest)


Autophagic LC3B aggregation is suppressed in $TAK1^{-/-}$ hepatocytes



Starvation-induced AMPK activation is inhibited in $TAK1^{-/-}$ hepatocytes





Rapamycin Restores Autophagy in TAK1^{-/-} Hepatocytes



(Inokuchi-Shimizu et al 2014, J Clin Invest)


Rapamycin Suppresses Liver Injury in *Tak1*^{ΔHEP} mice




(Inokuchi-Shimizu et al 2014, J Clin Invest)

Rapamycin Suppresses Liver Fibrosis in *Tak1* ^{Δ HEP} mice

Tak1 ^{Δ HEP} mice




Vehicle




rapamycin

Injection of 5mg/kgBW rapamycin 2 times/week from 28 to 36 weeks



The enhancement of toxin-induced liver fibrosis in fatty liver disease



Fatty liver disease changes the sensitivity to toxin exposure that enhances liver fibrosis


High fat diet




Chronic Industrial Toxin Exposure



Healthy Liver




Fatty Liver



Liver Cirrhosis





Acknowledgement

UC San Diego **Superfund Research Center**

Ekihiro Seki MD, PhD (Project5)
David A. Brenner MD (Co-leader)

Robert Tukey PhD (Director)

Michael Karin PhD (Project 1)

Koji Taniguchi MD, PhD

XieFeng Wu PhD

Yoon Seok Roh DVM, PhD
Shuang Liang PhD
Hiroshi Matsushita MD, PhD
Sayaka Inokuchi-Shimuzu MD, PhD
Ling Yang MD, PhD
Bi Zhang
Jingyi Song

Mark Ellisman PhD (Core)

Mason Mackey